Stem-cell therapy

Visiongain publishes Global Stem Cell Technologies and Applications Market 2020-2030 report

Retrieved on: 
Monday, August 24, 2020
Articles, Branches of biology, Biology, Stem cells, Biotechnology, Cell biology, Cloning, Developmental biology, Science, technology, engineering, and mathematics, Stem-cell therapy

How will the main segments within the overall stem cells market develop between 2020-2030?

Key Points: 
  • How will the main segments within the overall stem cells market develop between 2020-2030?
  • What are the main drivers and restraints that will shape the overall stem cells market, and its individual segments over the next ten years?
  • What are the main strengths, weaknesses, opportunities and threats for the stem cell market?
  • Visiongain's study is intended for anyone requiring commercial analyses for the Global Stem Cell Technologies and Applications Market.

Aroa Biosurgery’s Endoform® Platform Shown to Attract Stem Cells

Retrieved on: 
Wednesday, August 19, 2020
Health, Medical devices, Stem cells, Surgery, Genetics, Clinical trials, Biotechnology, Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Induced stem cells, Developmental biology, Regenerative biomedicine, Tissue engineering, Stem-cell therapy

Aroas lead scientist for the study, Dr Sandi Dempsey, said the paper describes the ability of components found within the Endoform ECM platform technology to signal stem cells in laboratory models.

Key Points: 
  • Aroas lead scientist for the study, Dr Sandi Dempsey, said the paper describes the ability of components found within the Endoform ECM platform technology to signal stem cells in laboratory models.
  • Endoform contains a vast number of proteins that interact with a patients own cells to support the repair of damaged tissue in different ways.
  • This data suggests that one such mechanism occurs by recruiting stem cells from the surrounding healthy tissue to support soft tissue repair, Dr Dempsey says.
  • That we have shown Endoform attracts stem cells to the site of tissue damage goes one step further towards unlocking the full regenerative capacity of Endoform.

BrainStorm to Present at the 40th Annual Canaccord Genuity Growth Conference

Retrieved on: 
Monday, August 10, 2020
Branches of biology, Biology, Life sciences, Stem cells, Canaccord Genuity, Genuity, Stem-cell therapy

NEW YORK, Aug. 10, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Ralph Kern, MD, MHSc, President and Chief Medical Officer, will present a corporate overview during the 40th Annual Canaccord Genuity Growth Conference, to be held virtually August 11-13, 2020.

Key Points: 
  • NEW YORK, Aug. 10, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Ralph Kern, MD, MHSc, President and Chief Medical Officer, will present a corporate overview during the 40th Annual Canaccord Genuity Growth Conference, to be held virtually August 11-13, 2020.
  • Company management will also be available for 1on1 meetings with institutional investors via video conference on the day of the presentation.
  • To request a meeting, please contact your representative at Canaccord Genuity.
  • About BrainStorm Cell Therapeutics Inc.
    BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.

Avacta and Daewoong Pharmaceutical expand partnership to include COVID-19 neutralising Affimer therapy

Retrieved on: 
Wednesday, July 29, 2020
Health, Infectious diseases, Stem cells, Clinical trials, Research, Science, Pharmaceutical, Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Emerging technologies, Affimer, Induced stem cells, Cell biology, Stem-cell therapy, Gene therapy, Mesenchymal stem cell

Stem cell therapies offer a very promising approach to repair the damage to lung tissues in these pulmonary diseases by controlling the immune balance.

Key Points: 
  • Stem cell therapies offer a very promising approach to repair the damage to lung tissues in these pulmonary diseases by controlling the immune balance.
  • AffyXell Therapeutics, the next-generation cell and gene therapy joint venture between Avacta and Daewoong Pharmaceutical, is developing a novel class of mesenchymal stem cell (MSC) treatments that are engineered to also produce Affimer therapies in the patient at the site of action.
  • The expansion of the agreement between Avacta, Daewoong Pharmaceutical and AffyXell announced today extends the scope of the partnership to include Affimer molecules that target viruses, such as coronaviruses, in order to develop therapies that repair the lung damage caused by COVID-19 whilst also producing neutralising Affimer molecules to prevent the progression of the disease.
  • Seng-ho Jeon, CEO of Daewoong Pharmaceutical and AffyXell Therapeutics, commented:
    It is very encouraging that AffyXell now has the opportunity to expand the application of its next-generation stem cell platform technology to target viruses.

BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Corporate and R&D Update

Retrieved on: 
Monday, July 27, 2020
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Mesenchymal stem cell, Adult stem cell, Induced stem cells, Stem-cell therapy

MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.

Key Points: 
  • MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.
  • BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS).
  • BrainStorm Cell Therapeutics Inc.is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.
  • Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Boehringer Ingelheim acquires GST to strengthen its stem cell capabilities in Animal Health

Retrieved on: 
Monday, July 27, 2020
Health, Stem cells, Research, Science, Pharmaceutical, Biotechnology, Veterinary, Branches of biology, Biology, Life sciences, Boehringer Ingelheim, Stem cells, Biotechnology, Boehringer, Ingelheim am Rhein, Stem-cell therapy

Boehringer Ingelheim, a market leader in animal health, has acquired Global Stem cell Technology (GST), a Belgian veterinary biotech company.

Key Points: 
  • Boehringer Ingelheim, a market leader in animal health, has acquired Global Stem cell Technology (GST), a Belgian veterinary biotech company.
  • GST is dedicated to the research, development and production of evidence-based, regenerative medicines (stem cell therapies) used to treat orthopedic and metabolic diseases in animals.
  • Boehringer Ingelheim already entered into a partnership with GST in 2018; in 2019, the companies launched Arti-Cell Forte in Europe.
  • The acquisition and integration of GST will accelerate the development pipeline of Boehringer Ingelheim while maintaining its focus on setting new standards of care for animals.

Global Stem Cell Therapy Market Analysis Highlights the Impact of COVID-19 2020-2024| Increase in Awareness of Stem Cell Therapy to Boost Market Growth | Technavio

Retrieved on: 
Monday, July 27, 2020
Health, Stem cells, Branches of biology, Life sciences, Biology, Stem cells, Biotechnology, Induced stem cells, Emerging technologies, Developmental biology, Stem-cell therapy, Therapy

Download a Free Sample Report on COVID-19 Impacts

Key Points: 
  • Download a Free Sample Report on COVID-19 Impacts
    What was the size of the stem cell therapy market in 2019?
  • An increase in awareness of stem cell therapy has been instrumental in driving the growth of the market.
  • An increase in awareness of stem cell therapy has been instrumental in driving the growth of the market.
  • Stem Cell Therapy Market 2020-2024: Segmentation
    Stem Cell Therapy Market is segmented as below:

R3 International Offering New Program for Stem Cell Therapy for Degenerative Disc in Mexico

Retrieved on: 
Tuesday, July 21, 2020
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Degenerative disc disease, Stem-cell therapy, Cell therapy, Back pain

SCOTTSDALE, Ariz., July 21, 2020 /PRNewswire-PRWeb/ --R3 International is now offering a new program for stem cell therapy for degenerative disc disease in Mexico .

Key Points: 
  • SCOTTSDALE, Ariz., July 21, 2020 /PRNewswire-PRWeb/ --R3 International is now offering a new program for stem cell therapy for degenerative disc disease in Mexico .
  • The back pain program starts with a free phone consultation with an R3 licensed, experienced stem cell doctor.
  • R3 provides travel from the San Diego airport to the stem cell clinic in Mexico, which is only 20 minutes away.
  • In addition to treating degenerative disc disease, R3 also offers stem cell treatment for knees , hips, shoulders, post-stroke, RA, MS, ALS, Lyme, kidney failure and more.

Researchers Discover a New Type of Cells That May Predict Flares in Rheumatoid Arthritis

Retrieved on: 
Thursday, July 16, 2020
Branches of biology, Biology, Stem cells, Life sciences, Blood, Stem-cell therapy, Induced stem cells

The researchers obtained samples from 364 time points from eight flares over four years from the first patient.

Key Points: 
  • The researchers obtained samples from 364 time points from eight flares over four years from the first patient.
  • They discovered a new type of cell in circulating blood that they named PRIME cells (PRe-Inflammatory MEsenchymal) cells.
  • The number of PRIME cells increased in circulating blood before flares occurred and decreased during flares in all four patients.
  • Dr. Orange and colleagues also observed that immune cells called B cells were activated in blood before flares occurred.

R3 International Offering New Stem Cell Therapy for Diabetes Program in Mexico

Retrieved on: 
Wednesday, July 15, 2020
Branches of biology, Biology, Medicine, Stem cells, RTT, Biotechnology, Rheumatology, Cell biology, Stem-cell therapy, Arthritis, Mesenchymal stem cell, Type 1 diabetes

SCOTTSDALE, Ariz., July 15, 2020 /PRNewswire-PRWeb/ --R3 International is now offering a new stem cell therapy program for diabetes in Mexico, with pricing starting at only $2950.

Key Points: 
  • SCOTTSDALE, Ariz., July 15, 2020 /PRNewswire-PRWeb/ --R3 International is now offering a new stem cell therapy program for diabetes in Mexico, with pricing starting at only $2950.
  • R3 International uses mesenchymal stem cells obtained from umbilical cord tissue, from consenting donors after a scheduled c-section.
  • The stem cell treatment clinic in Mexico is only twenty minutes from the San Diego airport, and ground transportation is included.
  • In addition to effective diabetes treatment, R3 International also offers stem cell therapy for arthritis , neuropathy, stroke, dementia, MS, ALS, autism, Lyme, rheumatoid arthritis, Crohns and more.